# ADIA MED, INC. (ADIA) · Edgar & Edgarette company card

> Adia Med (ADIA) grew revenue 10880% in FY2025 to $1 million, operating margin -52.3% against a 0.7% median for medicinal chemicals & botanical products, equity -43.3% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1160420 · fiscal year ended 2025-12-31 · 2 audited years read · [page](https://www.pops4.com/boards/company/ADIA) · [JSON](https://www.pops4.com/boards/company/ADIA.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $700,508 |
| Revenue growth, 1 year | 10879.7% |
| Revenue growth per year | — |
| Operating margin | -52.3% (prior year -2739.0%) |
| Net margin | -56.5% |
| Operating cash flow | −$179,228 |
| Capital spending | $13,200 |
| Free cash flow | −$192,428 |
| Cash | $79,392 |
| Long-term debt | — |
| Total assets | $594,826 |
| Total equity | −$257,674 |
| Equity ÷ assets | -43.3% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -91.82 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative (-$179K in FY2025); operating loss: a margin of -52.3% in FY2025; revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $701K (FY2025). Experience: revenue up 10879.7% on the year; operating margin -52.3%, up from -2739.0%. Soundness: equity -43.3% of assets (liabilities exceed assets). Credibility: 2 audited years, moderate weight. Range: 80% of past cases like this landed between $56.4M and $101.4M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (10 filers, $50M+ revenue, medicinal chemicals & botanical products): operating margin -52.3% against a 0.7% median; growth 10879.7% against 1.7%.

Range logged 2026-10-07, receipt 4719283f8822fb48, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

No warning filings in the window.

## Recent filings

- 10-Q · filed 2026-11-16 · [filing](https://www.sec.gov/Archives/edgar/data/1160420/000168316826008830/0001683168-26-008830-index.htm)
- 8-K · filed 2026-10-19 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1160420/000168316826007951/0001683168-26-007951-index.htm)
- 8-K · filed 2026-10-13 · 1.02 Termination of a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1160420/000168316826007770/0001683168-26-007770-index.htm)
- 8-K · filed 2026-10-06 · 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1160420/000168316826007632/0001683168-26-007632-index.htm)
- 8-K · filed 2026-10-05 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1160420/000168316826007624/0001683168-26-007624-index.htm)
- 8-K · filed 2026-08-24 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1160420/000168316826006679/0001683168-26-006679-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001160420.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1160420

## Cite

POPS4, Edgar & Edgarette: ADIA MED, INC. (ADIA) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/ADIA. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

